Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

CD105 expression on CD34-negative spindle-shaped stromal cells of primary tumor is an unfavorable prognostic marker in early breast cancer patients.

Martinez LM, Labovsky V, Calcagno ML, Davies KM, Garcia Rivello H, Bianchi MS, Wernicke A, Fernández Vallone VB, Chasseing NA.

PLoS One. 2015 Mar 24;10(3):e0121421. doi: 10.1371/journal.pone.0121421. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0126542. Rivello, Hernán Garcia [corrected to Garcia Rivello, Hernán]; Vallone, Valeria Beatriz Fernandez [corrected to Fernandez Vallone, Valeria Beatriz].

2.

Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer.

Labovsky V, Martinez LM, Calcagno ML, Davies KM, García-Rivello H, Wernicke A, Feldman L, Giorello MB, Matas A, Borzone FR, Howard SC, Chasseing NA.

Tumour Biol. 2016 Oct;37(10):13377-13384. Epub 2016 Jul 27.

PMID:
27460086
3.

Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in breast cancer patients.

Beketic-Oreskovic L, Ozretic P, Rabbani ZN, Jackson IL, Sarcevic B, Levanat S, Maric P, Babic I, Vujaskovic Z.

Pathol Oncol Res. 2011 Sep;17(3):593-603. doi: 10.1007/s12253-010-9355-6. Epub 2011 Jan 20.

PMID:
21249485
4.
5.

Comparative prognostic relevance of breast intra-tumoral microvessel density evaluated by CD105 and CD146: A pilot study of 42 cases.

Martinez LM, Labovsky V, Calcagno Mde L, Davies KM, Rivello HG, Wernicke A, Calvo JC, Chasseing NA.

Pathol Res Pract. 2016 Apr;212(4):350-5. doi: 10.1016/j.prp.2016.02.009. Epub 2016 Feb 2.

PMID:
26872535
6.

Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.

Bellone G, Solerio D, Chiusa L, Brondino G, Carbone A, Prati A, Scirelli T, Camandona M, Palestro G, Dei Poli M.

Ann Surg Oncol. 2007 Nov;14(11):3232-42. Epub 2007 Aug 8.

PMID:
17682823
7.

The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.

Medrek C, Pontén F, Jirström K, Leandersson K.

BMC Cancer. 2012 Jul 23;12:306. doi: 10.1186/1471-2407-12-306.

8.

Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.

Miyata Y, Mitsunari K, Asai A, Takehara K, Mochizuki Y, Sakai H.

Prostate. 2015 Jan;75(1):84-91. doi: 10.1002/pros.22894. Epub 2014 Oct 13.

9.

Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.

Safwat MD, Habib F, Elayat A, Oweiss N, Reffat S, Algaidi S.

Folia Morphol (Warsz). 2009 Aug;68(3):144-55.

PMID:
19722158
10.

Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination.

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Giercksky KE, Nesland JM.

Clin Cancer Res. 2008 Apr 15;14(8):2341-50. doi: 10.1158/1078-0432.CCR-07-4214.

11.

Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.

Zou A, Lambert D, Yeh H, Yasukawa K, Behbod F, Fan F, Cheng N.

BMC Cancer. 2014 Oct 24;14:781. doi: 10.1186/1471-2407-14-781.

12.
13.

Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.

Barresi V, Cerasoli S, Vitarelli E, Tuccari G.

Acta Neuropathol. 2007 Aug;114(2):147-56. Epub 2007 Jun 27.

PMID:
17594108
14.

Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905).

Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C.

Br J Cancer. 2004 Mar 22;90(6):1216-21.

15.

Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line.

Wang X, Liu Y, Zhou K, Zhang G, Wang F, Ren J.

Int J Clin Exp Pathol. 2015 May 1;8(5):5105-12. eCollection 2015.

16.

CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival.

Davidson B, Stavnes HT, Førsund M, Berner A, Staff AC.

Breast. 2010 Dec;19(6):493-8. doi: 10.1016/j.breast.2010.05.013. Epub 2010 Jun 17.

17.
18.

Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.

Labovsky V, Martinez LM, Davies KM, de Luján Calcagno M, García-Rivello H, Wernicke A, Feldman L, Matas A, Giorello MB, Borzone FR, Choi H, Howard SC, Chasseing NA.

BMC Cancer. 2017 Apr 18;17(1):280. doi: 10.1186/s12885-017-3259-8.

19.

Mesenchymal Stem Cell Marker Expression in Gastric Cancer Stroma.

Numakura S, Uozaki H, Kikuchi Y, Watabe S, Togashi A, Watanabe M.

Anticancer Res. 2019 Jan;39(1):387-393. doi: 10.21873/anticanres.13124.

PMID:
30591485
20.

[The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].

Charpin-Taranger C, Dales JP, Garcia S, Andrac-Meyer L, Ramuz O, Carpentier-Meunier S, Bonnier P.

Bull Acad Natl Med. 2003;187(6):1129-45; discussion 1145-6. French.

PMID:
14978873

Supplemental Content

Support Center